Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Universal Technical Institute (UTI) has been punished after a series of operational stumbles that look correctable. With a market cap around $1.15B, P/E near 33, negative free cash flow but manageable leverage, and technicals showing oversold readings, this is a trade to take on the expectation of operational fixes and enrollment stabilization. Ent…
MISTRAS Group, Inc., a global leader in industrial asset integrity and testing solutions, has entered into a definitive agreement to be acquired by affiliates of H.I.G. Capital in an all-cash transaction at $20.35 per share, representing an 8-13% premium over recent trading prices and a 61% increase since December 2025. The transaction, valued at a…
BioStem Technologies has entered into a $40 million committed equity facility agreement with Roth Principal Investments, enabling the company to issue shares of its common stock at its discretion to raise capital. The proceeds will be used for working capital and general corporate purposes, with no obligation to utilize the full amount. The facilit…
BlossomHill Therapeutics announced its Q2 2026 financial results, highlighted by a successful upsized IPO raising $168.3 million and FDA Fast Track designation for its drug candidate BH-30643 targeting advanced EGFR C797S-positive non-small cell lung cancer (NSCLC). The company presented promising clinical and preclinical data for their pipeline dr…
Rheinmetall sits at the intersection of structural defense demand and near-term execution risk. This note lays out a long-biased trade with precise entry, stop and target levels, explains the fundamental drivers and valuation logic, and highlights catalysts and risks that will move the stock over the next 180 trading days.
Dillard's, Inc. announced it will move its primary stock listings from the New York Stock Exchange to the Texas Stock Exchange in early October 2026. The move involves its Class A Common Stock (DDS) and 7.50% Capital Securities (DDT), retaining existing ticker symbols. This strategic transfer reflects the company's strong Texas roots, where it has …
Amcor (AMCR) trades at a reasonable multiple with a 6%+ yield, improving free cash flow and industry tailwinds in sustainable packaging. Short-term macro and merger-related noise have pressured the stock; we lay out a trade that captures an income cushion while targeting recovery to prior highs.
Alarm over advanced artificial intelligence dominated headlines early in the week as prominent industry figures urged a slowdown in model development. Market focus soon shifted to tangible economic pressures: a Federal Reserve interest rate rise and renewed disruptions to Middle East oil flows. Those developments pushed energy prices higher, sent m…
Vince (VNCE) just cleared a high hurdle: a Q2 beat and better DTC traction. The OVO acquisition is less an incremental bolt-on than a stress test of a new operating model. If Vince can convert sales mix and protect margins, valuation looks inexpensive relative to its FCF and EV/EBITDA. This is a mid-term swing trade: buy on weakness, size for a 45-…
Goldman Sachs reiterated a bullish end-2027 gold target of $5,400 an ounce even after a recent Federal Reserve rate increase and expectations for another hike in October. The bank expects higher rates to temper gold's near-term gains through ETF flows, but projects three Fed cuts between September 2027 and March 2028 and no change to the terminal r…
CDT Equity Inc. announced a strategic partnership with QIMA Life Sciences to evaluate novel combinations of their drug tapinarof (VTAMA®) for autoimmune skin diseases psoriasis and vitiligo. The collaboration leverages patient-derived human skin tissue for clinically relevant preclinical testing aimed at enhancing efficacy and expanding market reac…
Bimergen Energy Corporation (NYSE American: BESS) announced that its subsidiary Emergen Energy, LLC has completed SAM.gov registration and received a CAGE code, enabling it to compete for federal contracts and government assistance opportunities. This milestone aligns with the company's strategy to expand its market reach in energy storage infrastr…
Viomi Technology Co., Ltd announced that it has regained compliance with Nasdaq's minimum bid price requirement after its American Depositary Shares (ADSs) closed at or above $1.00 per ADS for 10 consecutive business days. This resolves prior non-compliance issues and reinforces the company's position on the Nasdaq exchange.
Pagaya (PGY) is a buy at $20.80. The company pairs strong recent revenue and free-cash-flow generation with below-peer valuation multiples and a shift toward fee-based, asset-light products that reduce interest-rate sensitivity. Entry $20.80, stop $17.00, target $30.00 over a 180-trading-day horizon.
Strive's stock climbed 3.8% in pre-market trading to $29.34 as investors moved into Bitcoin-sensitive equities following the Federal Reserve's September decision. The company reinforced its Bitcoin treasury strategy with a Form 8-K confirming the SATA preferred dividend rate and a disclosure that it bought 469 additional bitcoin, bringing holdings …
<p>CT3 will appear on the speaker roster at CoinFerenceX Singapore 2026, with CTO and Head of Partnerships & Governance Leandro Gomes scheduled to present on NFTs as access tools, enterprise adoption of Web3, and decentralized data storage. The event takes place October 5-6 at Flower Field Hall, Gardens by the Bay. CT3 aims to use the conference to…
Faeth Therapeutics (FTH) is a clinical-stage immunotherapy company trading at a market cap near $900M. We prefer FTH ahead of a year-end 2026 PIKTOR endometrial cancer (EC) data readout and the program's planned expansion into HR+/HER2- breast cancer. The combination of Fast Track designation, a compact float, and modest short interest creates an a…
Brookfield Asset Management (BAM) offers a 4.3% yield, strong free cash flow ($2.31B) and multiple growth levers including a recent $2.8B acquisition. Near-term technicals are oversold and valuation can re-rate if asset monetization and fee growth accelerate.
Vor Biopharma looks like a funded replication bet: telitacicept delivered a meaningful clinical signal in China and the company has since raised capital to advance global development. At a market cap of about $1.29B and with active short interest, the stock offers a high-risk, high-reward trade if upcoming clinical and execution milestones confirm …
LB Pharmaceuticals (LBRX) is a small-cap biotech advancing LB-102, a Phase 3-ready oral antipsychotic for acute schizophrenia. With topline NOVA-2 results moved into H1 2027 and a balance sheet that management says funds operations through Q2 2029, the stock looks like a buyable pullback around $42. This long trade targets $60 over a 180 trading da…
We upgrade TransMedics (TMDX) to a tactical long ahead of multiple 2027 clinical and commercial catalysts. The company is growing revenue (Q2 revenue $189.9M, +20.7% YoY) while reinvesting heavily in kidney OCS expansion and manufacturing, compressing near-term margins. At a $3.0B market cap and P/E around 19.8, the valuation already reflects a mix…
SK hynix sits at the intersection of memory, custom packaging and system-level AI acceleration. This trade idea argues for a defined long with a mid-to-long-term horizon, capitalizing on continued AI server deployments and the company’s deep NAND/DRAM integration. Entry, stop and targets are provided with catalysts and balanced risks.
Taboola announced its intent to acquire Dianomi, a specialist digital advertising provider to premium finance and business clients. The acquisition, pending regulatory and shareholder approvals, is expected to enhance Taboola's performance advertising capabilities, especially through its Realize platform, by integrating Dianomi's specialized premiu…
Brookfield trades near its 52-week low while fundraising momentum, an expanding Wealth & Insurance mix, and a likely investor-day update create a clear, actionable swing trade. Technicals show oversold conditions and elevated short activity that can fuel a quick rebound. I recommend a tactical long with defined risk and a mid-term horizon tied to u…
Barclays has initiated coverage of Hill & Smith with an overweight rating and a 3,300 pence price target, pointing to the group's exposure to U.S. grid modernization, transmission and distribution, and data-center investment. The broker projects roughly 7% organic growth over fiscal 2026-28 and expects earnings per share to compound around 11% annu…
